Additionally, GW2580, an orally bioavailable and selective CSF1R kinase inhibitor, reduced cell viability in both ibrutinib-sensitive and resistant primary MCL cells, indicating that targeting the CSF1/CSF1R axis could be an effective approach for treating ibrutinib-resistant patients. This evidence concerns the gene CSF1 and mantle cell lymphoma.